1. Why Hunan Pharmaceutical Manufacturing Is Worth a Separate Look

Pharmaceutical manufacturing is an industry of wide span. At one end it connects to traditional-medicine formulas brewed over centuries; at the other, to molecular diagnostics that use gene amplification for screening conditions such as COVID and cervical cancer. It includes finished-drug factories making tablets and capsules, as well as supporting firms dedicated to supplying others with active pharmaceutical ingredients and excipients. Placed together in one province, these are easily masked by a single aggregate "pharmaceutical output" figure, which hides how many utterly different things actually grow inside.

Hunan happens to be a sample well suited to being taken apart. Its pharmaceutical manufacturing has two distinct features: high concentration in Changsha, and old and new crowded onto the same map. In recent years, the single city of Changsha gathered nearly sixty percent of the province's related firms, with the Xiangjiang New Area, the Liuyang development zone and Jinxia pinning the industry firmly to the two banks of the Xiang River. Within this small geography stand both Jiuzhitang, a heritage traditional-medicine name traceable to 1650, and Zhuzhou's Qianjin Pharmaceutical, founded in 1966, alongside Sansure Biotech, which began in molecular diagnostics and reported revenue of about 1 billion yuan in 2023. A central province famed for being "old" places, on its pharmaceutical line, two bets at once: traditional medicine and frontier diagnostics.

The Institute takes up Hunan's pharmaceutical manufacturing not because its total scale ranks at the very top of the country, but because it clearly displays one question: can a province with a deep traditional-medicine base also hold its ground in more technical, more upstream links such as molecular diagnostics, excipients and active ingredients. This article endorses no investment judgment. It only sets out the real landscape of the Hunan line and honestly points to where it remains incomplete.

2. Changsha: One City Gathering Nearly Sixty Percent of the Provincial Map

To speak of Hunan pharmaceutical manufacturing is to be unable to bypass Changsha. Hunan's pharmaceutical industry is not spread evenly across the province but is highly concentrated in the provincial capital. According to public reports, Changsha alone has gathered over a thousand related firms, accounting for nearly sixty percent of the provincial total, placing the greater part of Hunan pharmaceutical manufacturing's weight on the two banks of the Xiang River.

Changsha's concentration further divides among several parks. The area around the Xiangjiang New Area centers on traditional medicine and medical devices, a stronghold of the province's traditional-medicine manufacturing and device development. The Jinxia development zone, leveraging a base dense in pharmaceutical-distribution enterprises and top-tier hospitals, has built medical devices and pharmaceutical sales to considerable scale, and is trying to turn its past distribution advantage into a manufacturing advantage. The medical-device line deserves a particular note: according to public reports, Changsha's medical-device industry has grown from over 8 billion yuan in 2018 to the scale of 30 billion yuan in 2023, multiplying several times over those years to become the fastest-growing piece of Changsha's pharmaceutical map.

Singling out Changsha reveals that the story of Hunan pharmaceutical manufacturing is in fact the story of one city. The benefit of high cluster concentration is nearby supporting work, fast coordination and concentrated policy resources. Its other side is that the fate of the whole province's industry hinges to a large degree on the success or failure of one city; apart from Zhuzhou, the province's other prefectures find it hard to form a second pole alongside Changsha in pharmaceutical manufacturing.

3. The Liuyang Development Zone: The Largest Biopharma Cluster in the Province

If Changsha is the center of gravity of Hunan pharmaceuticals, the Liuyang Economic and Technological Development Zone is the densest single point within that center.

The Liuyang zone is a national-level park and the site of the Changsha national biological-industry base. According to disclosures by Hunan's industry and information-technology authorities, more than 180 biopharmaceutical enterprises here are in production and registered, including several listed firms and dozens of national high-tech enterprises, making it the largest biopharmaceutical cluster in the province. The locality has set its goal on enlarging the biopharmaceutical industry's scale, continuously introducing leading firms, building platforms and cultivating upstream and downstream around the park.

What is special about the Liuyang park is that it blends the traditional and the emerging. The park holds both firms such as Erkang Pharmaceutical, which began in excipients, and a group of new-format makers of medical-cosmetic dressings, light medical-aesthetic equipment, in-vitro diagnostics and rehabilitation devices. According to public reports, the medical-device-related firms in the Liuyang zone have formed several business sectors including high-end medical-cosmetic dressings, light medical-aesthetic equipment, in-vitro diagnostics and rehabilitation devices. That a county-level city's development zone can raise the lines of finished drugs, excipients and medical devices at the same time itself shows that the density of Hunan pharmaceutical manufacturing is concentrated and expressed precisely in parks such as Liuyang.

The foundation of this path is pinning scattered firms together through an industrial park, then pulling the upstream and downstream along with leading firms. Whether it can keep climbing depends on whether the park can move from "gathering many" to "growing tall," pushing more firms from contract work and supporting roles toward positions with their own products and research barriers.

4. Jiuzhitang and Qianjin: The Old Foundation of Hunan Pharmaceuticals

The thickest base layer of Hunan pharmaceutical manufacturing is traditional medicine, and on this line stand two signboards: Jiuzhitang and Qianjin Pharmaceutical.

Jiuzhitang's history reaches far back. Its predecessor was a pharmacy founded in 1650 on Pozi Street in Changsha, formally named "Jiuzhitang" in 1782, recognized as a "China Time-Honored Brand" in 2006, with its traditional-medicine culture also inscribed on the national list of intangible cultural heritage. After the founding of New China, this old pharmacy moved through public-private joint operation and restructuring to form a joint-stock company in 1999 and list on the Shenzhen Stock Exchange in 2000. It is now a modern pharmaceutical enterprise with more than thirty subsidiaries, covering cardio-cerebrovascular, kidney-tonifying, blood-tonifying, women's and children's and other fields, with Shuxuetong injection, donkey-hide blood-nourishing granules and Liuwei Dihuang pills among its core varieties. That a brand starting from an old Pozi Street pharmacy could operate continuously in Changsha for more than three centuries and reach the capital market is itself the weightiest entry in Hunan pharmaceutical manufacturing.

South to Zhuzhou stands another traditional-medicine signboard: Qianjin Pharmaceutical. It was founded in 1966 and listed on the Shanghai Stock Exchange in 2004. Its best-known product is the Fuke Qianjin tablet: this medicine obtained its production license in 1979 and has long been a Class-A variety in the national medical-insurance catalogue, gained protection as a national protected traditional-medicine variety in 2002, and saw the "Qianjin" trademark recognized as a China well-known trademark. Around the line of women's health, Qianjin has turned a single gynecological traditional medicine into a signature product capable of standing in the province for decades.

What these two signboards share is that both have made "age" into a moat, relying on brand trust accumulated over the years and protected exclusive varieties, not on being cheap. They also together form the layer that distinguishes Hunan pharmaceutical manufacturing from purely chemical-drug provinces: the weight of traditional medicine is heavy.

5. Sansure, Erkang and Warner: The Lines Climbing Upstream and Toward the Frontier

Were Hunan pharmaceuticals only heritage traditional medicine, the story would lean old. What makes this map new are several more upstream, more technical lines: molecular diagnostics, excipients and active ingredients.

The most representative is Sansure Biotech. This in-vitro diagnostics enterprise based in Changsha began in molecular diagnostics, with its main business in nucleic-acid testing reagents and supporting instruments, and is an important member of the domestic in-vitro diagnostics field. According to its annual report, in 2023 the company achieved revenue of about 1 billion yuan, with research investment of about 236 million yuan, exceeding twenty percent of revenue; over the same period its regular-reagent business grew rapidly in sales, and it won bids in inter-provincial alliance centralized volume-based procurement for cervical-cancer-related testing. Its significance lies in adding, to a Hunan pharmaceutical map strong in traditional medicine, a piece that relies on technology and research and keeps close to the frontier of precision testing.

Another line climbing upstream is excipients. Liuyang's Erkang Pharmaceutical, founded in 2003, is one of the domestic excipient industry's firms with a relatively full range of varieties and relatively large scale, with excipient and active-ingredient varieties numbering in the hundreds. Its most emblematic product is the starch plant capsule with independent intellectual property, using starch in place of traditional gelatin for the capsule shell, with the related standard already included in the Chinese Pharmacopoeia. That a firm dedicated to excipients can produce its own technology in the matter of "supporting others" is a rare upstream sample in Hunan pharmaceuticals.

A third line is the integration of active ingredients and formulations. Warner Pharmaceutical, in the Wangcheng and Liuyang area, was founded in 2001, with its main business in the research, production and sale of high-end chemical drugs and traditional medicine, its products covering fields such as digestion, respiration and anti-infection. It has laid out several production bases in Hunan for chemical active ingredients, chemical-drug formulations, plant-extract raw materials and traditional Chinese patent medicines, opening up both the chain "from chemical active ingredients to chemical-drug formulations" and the chain "from traditional-medicine extraction to patent medicines." Such an integrated layout means Hunan pharmaceutical manufacturing is not only making finished drugs but also has its own place in the more forward links of active ingredients and extracts.

The value of these three lines lies in characters entirely different from the heritage traditional medicine: Jiuzhitang and Qianjin compete on the time-sedimentation of brand and exclusive varieties, while Sansure competes on the technology and research of molecular diagnostics, Erkang on the proprietary craft of excipients, and Warner on the depth of a chain from raw material to formulation. Their scale may not all be the largest, but they represent the part of Hunan pharmaceutical manufacturing climbing toward technology and the upstream.

6. Weaknesses and the Institute's Judgment

Drawing the several lines together, Hunan's pharmaceutical manufacturing takes on a shape of "one city dominant, old and new in one frame." Geographically it is highly concentrated in Changsha, with the Xiangjiang New Area, the Liuyang development zone and Jinxia gathering nearly sixty percent of the province's firms, and the Liuyang zone the largest biopharmaceutical cluster in the province with more than 180 firms in production. Industrially, two layers stack together: below lies the old traditional-medicine base of names such as Jiuzhitang and Qianjin, traceable across centuries and near sixty years; above lie the more technical, more upstream new forces of Sansure's molecular diagnostics, Erkang's excipients and Warner's integrated active-ingredient-to-formulation chain. Within one province, those brewing traditional medicine and those doing gene amplification stand on the same map.

Its weaknesses are also clearly divided. First is over-reliance on the single city of Changsha; the fate of the whole province's industry hinges to a large degree on the success or failure of the capital's parks, with no second pole standing alongside it apart from Zhuzhou. Second, while heritage traditional-medicine names are thick, they generally face the test of slowing growth in old varieties and how to keep launching new ones; a moat accumulated over time also needs new products to continue it. Third, while new lines such as molecular diagnostics and medical devices are pointed in the right direction and grow fast, a considerable part still leans toward testing and devices, and the force truly able to stand in the highest-value-added link of innovative drugs remains limited. Each line has its own weakness, and they are hard to capture with a single unified judgment.

For sales teams making upstream supply to Hunan's pharmaceutical manufacturers, whether supplying medicinal herbs and extracts, chemical active ingredients and intermediates, excipients and packaging materials, or diagnostic-reagent raw materials and pharmaceutical equipment, reaching Hunan's pharmaceutical-manufacturing factory customers in volume is possible through Tianxia Gongchang, which lets you filter the factory directory and decision-maker contacts of Hunan's pharmaceutical manufacturing along both region and sector, turning upstream sales prospecting from asking around one by one into reading a map.

The Institute's view is this: the true point of interest in Hunan's pharmaceutical manufacturing lies not in how high Changsha's industry scale can be piled, but in whether this city can let the old and the new each complete its own advance: whether heritage names such as Jiuzhitang and Qianjin can launch new pillar products while holding their exclusive varieties, whether new forces such as Sansure can take one more step from testing toward higher-value-added links such as innovative drugs, and whether parks such as Liuyang and Jinxia can truly turn "gathering many firms" into "products that hold up." These questions share no common solution, yet together they decide whether Hunan pharmaceutical manufacturing can move from a present of "relying on one city and one old foundation" toward a more dimensional and more durable next stage. For an industry masked by the broad word "pharmaceutical," the real layering often hides in the seam where old and new share one frame.

Data Sources

  • Tianxia Gongchang (factory directory and industry data for Hunan's pharmaceutical manufacturing industry)
  • Hunan Department of Industry and Information Technology and the MIIT Torch Center: Hunan biopharmaceutical clusters and the number of biopharmaceutical firms in production, listed and high-tech enterprises in the Liuyang development zone
  • Changsha biopharmaceutical industry development briefing, Rednet and Changsha Evening News: the share of Changsha pharmaceutical-related firms in the provincial total, the industry-scale targets of the biological-economy three-year action plan and the positioning of each park
  • Changsha Evening News and the Hunan Provincial Government portal: the growth of Changsha's medical-device industry scale from 2018 to 2023
  • Jiuzhitang Co., Ltd. official site, the Ministry of Commerce Time-Honored Brand digital museum and Wikipedia: Jiuzhitang's founding and naming years, its time-honored brand and intangible-cultural-heritage recognition, listing history and core varieties
  • Qianjin Pharmaceutical official site and public materials on Zhuzhou Qianjin: Qianjin's founding year, listing date, the Fuke Qianjin tablet license and its national protected traditional-medicine variety and well-known trademark recognition
  • Sansure Biotech Co., Ltd. annual report: 2023 revenue, research investment and its share, regular-reagent business and centralized volume-based procurement bid wins
  • Hunan Erkang Pharmaceutical Co., Ltd. official site and public materials, Hunan Department of Industry and Information Technology: Erkang's founding year, scale of excipient and active-ingredient varieties, the starch plant capsule and its inclusion in the Chinese Pharmacopoeia
  • Hunan Warner Pharmaceutical Co., Ltd. official site, Hunan Department of Industry and Information Technology: Warner's founding year, main business and its two chains from chemical active ingredients to formulations and from traditional-medicine extraction to patent medicines